Top 20 Monsoon-Related Indian Stocks in Healthcare, Pharma & Agriculture (2025)

Explore 20 Indian stocks poised for monsoon-driven growth in 2025 across healthcare, pharma, and agriculture sectors. Includes fundamentals, PE, SMA, and RSI insights.



 Agriculture & Agrochemical Stocks

  1. UPL Ltd (NSE: UPL)

    • Market Cap: ₹74,000 Cr

    • P/E Ratio: ~15

    • SMA Trend: Neutral

    • RSI: ~50

    • Insights: Posted a surprise Q4 profit; expects 4%-8% revenue growth in FY25, driven by sustainable agriculture portfolio. 

  2. Coromandel International Ltd (NSE: COROMANDEL)

    • Market Cap: ₹32,000 Cr

    • P/E Ratio: ~18

    • SMA Trend: Neutral

    • RSI: ~55

    • Insights: Leading player in fertilizers and crop protection; benefits from favorable monsoon forecasts.

  3. Fertilisers And Chemicals Travancore Ltd (NSE: FACT)

    • Market Cap: ₹58,090.89 Cr

    • P/E Ratio: 397.39

    • 5Y CAGR: 87.59%

    • Insights: Strong growth trajectory; significant beneficiary of increased agricultural activities during monsoon. 

  4. Titan Biotech Ltd (NSE: TITANBIO)

    • Market Cap: ₹571.81 Cr

    • P/E Ratio: 23

    • 5Y CAGR: 77.29%

    • Insights: Provides biotech products essential for agriculture; poised for growth with monsoon-driven demand.

  5. Deepak Fertilisers and Petrochemicals Corp Ltd (NSE: DEEPAKFERT)

    • Market Cap: ₹14,333.67 Cr

    • P/E Ratio: 32.39

    • 5Y CAGR: 64.4%

    • Insights: Key player in fertilizers; expected to benefit from increased agricultural activities. 

  6. Best Agrolife Ltd (NSE: BESTAGRO)

    • Market Cap: ₹1,500 Cr

    • P/E Ratio: ~12

    • SMA Trend: Strong Downtrend

    • RSI: 29.47 (Oversold)

    • Insights: Despite the current downtrend, potential for recovery with favorable monsoon conditions. 

 Pharmaceutical Stocks

  1. Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA)

    • Market Cap: ₹4,15,000 Cr

    • P/E Ratio: ~30

    • SMA Trend: Neutral

    • RSI: 54.95

    • Insights: Q3 profit beat estimates due to strong domestic sales; robust performance expected to continue. 

  2. Cipla Ltd (NSE: CIPLA)

    • Market Cap: ₹1,00,000 Cr

    • P/E Ratio: ~25

    • SMA Trend: Neutral

    • RSI: ~50

    • Insights: Strong presence in respiratory and chronic therapies; steady performance anticipated.

  3. Dr. Reddy's Laboratories Ltd (NSE: DRREDDY)

    • Market Cap: ₹1,20,000 Cr

    • P/E Ratio: ~20

    • SMA Trend: Neutral

    • RSI: ~55

    • Insights: Diversified portfolio with global presence; positioned for consistent growth.

  4. Aurobindo Pharma Ltd (NSE: AUROPHARMA)

    • Market Cap: ₹45,000 Cr

    • P/E Ratio: ~12

    • SMA Trend: Neutral

    • RSI: ~50

    • Insights: Strong generic pipeline; expected to benefit from global demand.

  5. Piramal Pharma Ltd (NSE: PPLPHARMA)

    • Market Cap: ₹8,000 Cr

    • P/E Ratio: ~20

    • SMA Trend: Neutral

    • RSI: 58.48 (Uptrend)

    • Insights: Positive technical indicators suggest potential for upward movement.

  6. Mankind Pharma Ltd (NSE: MANKIND)

    • Market Cap: ₹90,000 Cr

    • P/E Ratio: ~25

    • SMA Trend: Neutral

    • RSI: 37.28 (Downtrend)

    • Insights: Recent downtrend; monitoring required for potential recovery.

  7. Sanofi India Ltd (NSE: SANOFI)

    • Market Cap: ₹12,000 Cr

    • P/E Ratio: ~30

    • SMA Trend: Neutral

    • RSI: 59.36 (Uptrend)

    • Insights: Strong uptrend indicators; favorable outlook.

  8. AstraZeneca Pharma India Ltd (NSE: ASTRAZEN)

    • Market Cap: ₹20,000 Cr

    • P/E Ratio: ~35

    • SMA Trend: Neutral

    • RSI: 69.21 (Uptrend)

    • Insights: Positive momentum; potential for continued growth.

  9. Sun Pharma Advanced Research Company Ltd (NSE: SPARC)

    • Market Cap: ₹3,000 Cr

    • P/E Ratio: ~15

    • SMA Trend: Strong Downtrend

    • RSI: 18.78 (Oversold)

    • Insights: Currently oversold; potential for rebound with positive developments.

 Healthcare & Hospital Stocks

  1. Max Healthcare Institute Ltd (NSE: MAXHEALTH)

    • Market Cap: ₹35,000 Cr

    • P/E Ratio: ~40

    • SMA Trend: Uptrend

    • RSI: 70.54 (Strong Uptrend)

    • Insights: Strong technical indicators; poised for continued growth.

  2. Indraprastha Medical Corporation Ltd (NSE: INDRAMEDCO)

    • Market Cap: ₹1,500 Cr

    • P/E Ratio: ~15

    • SMA Trend: Strong Downtrend

    • RSI: 28.09 (Oversold)

    • Insights: Currently in downtrend; monitoring for potential recovery.

  3. Apollo Hospitals Enterprise Ltd (NSE: APOLLOHOSP)

    • Market Cap: ₹70,000 Cr

    • P/E Ratio: ~50

    • SMA Trend: Neutral

    • RSI: ~55

    • Insights: Leading healthcare provider; stable performance expected.

  4. Fortis Healthcare Ltd (NSE: FORTIS)

    • Market Cap: ₹10,000 Cr

    • P/E Ratio: ~25

    • SMA Trend: Neutral

    • RSI: ~50

    • Insights: Consistent performance; potential for steady growth.

  5. Medanta (Global Health Ltd) (NSE: MEDANTA)

    • Market Cap: ₹15,000 Cr

    • P/E Ratio: ~30

    • SMA Trend: Neutral

    • RSI: ~55

    • Insights: Expanding presence; expected to benefit from increased healthcare demand.

Disclaimer for Monsoon-Related Stocks Analysis

The data presented reflects the most recent information available up to June 2025. Individuals considering investments are advised to perform independent research or seek guidance from qualified financial professionals prior to making any decisions.


Welcome to The Financial and Tech Literacy! I’m Awdhesh Kumar, a finance and tech enthusiast with 20+ years of experience in accounts, taxation, and the stock market. This blog simplifies finance and digital topics for all—students, professionals, retirees, and new investors. Learn about stock market strategies, personal finance, mutual funds, tech tools, digital banking, and government schemes. All content is original, practical, and based on real experience—no paid promotions or clickbait. We refer to trusted sources like SEBI, RBI, NSE, and Economic Times. Stay updated, make informed decisions, and grow financially with us. For contact: awdheshdube65@gmail.com.

Comments

Post a Comment